Abstract 2054
Background
Oncology patients with advanced disease frequently undergo Radiation to relieve symptoms such as pain and dyspnoea. These patients have been treated by different health professionals in multiple, complexed and long-term treatments. The goal of this study was to investigate the possibility to help and improve the quality of life of these patients.
Trial design
In the present study, 32 patients participated and were evaluated prospectively. The main criteria for their participation were the following: oncology patients >18 years old with a satisfactory level of verbal communication and advance cancer receiving radiotherapy. EORTC questionnaires (QLQ-C30) and questionnaire for problems and needs for palliative care PNCP-Center for the Quality of Care of the WOK research were used.The quality of life of these patients was assessed prior the beginning of the treatment and that was taken as a quality of life baseline level as well as at the end of their treatment. The present study was conducted from June 2018 to December 2018 in the Radiotherapy Department of "Hygeia" Hospital in Greece. Of the 32 patients who were evaluated 11 were women and 21 were men. Their average age was 65 years old. Also 84,4% of these patients had external help (family, caretaker). A significant improvement in the quality of life was observed only in patients who had home help for 4 hours daily (p.value 0,006).Men seemed to improve the quality of life after treatment (p.value 0,005).The patients reported their palliative care needs in the following rating scale: financial and phychological issues, autonomy, daily activities, spiritual issues, organic symptoms and need for information ,all of which will be presented in detail. Those who have difficulty completing tasks need or depent on others and ask for professional help (p.value 0,001)Radiation therapy alleviates the organic symptoms of patients with advanced disease, but it does not cover their needs that have become more important to them than their organic symptoms. Care for these patients needs a more specialized approach which incorporates the principles of palliative care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
2901 - IFN-γ/IL-10 ratio as predictive biomarker for response to anti-PD-1 therapy in metastatic melanoma patients
Presenter: Emilio Giunta
Session: Poster Display session 3
Resources:
Abstract
2306 - Multiplex Chromogenic Immunohistochemistry (IHC) for Spatial Analysis of Checkpoint-Positive Tumor Infiltrating Lymphocytes (TILs)
Presenter: Scott Ely
Session: Poster Display session 3
Resources:
Abstract
1678 - The role of PD-L1 expression as a predictive biomarker in advanced renal cell carcinoma: a meta-analysis of randomized clinical trials.
Presenter: Alberto Carretero-Gonzalez
Session: Poster Display session 3
Resources:
Abstract
5138 - Radiomic Features as a Non-invasive Biomarker to Predict Response to Immunotherapy in Recurrent or Metastatic Urothelial Carcinoma
Presenter: Kye Jin Park
Session: Poster Display session 3
Resources:
Abstract
5800 - Integrative combination of high-plex digital profiling techniques and cluster analysis to reveal complex immune biology in the tumor microenvironment of mesothelioma
Presenter: Carmen Ballesteros-Merino
Session: Poster Display session 3
Resources:
Abstract
5736 - Predictive factors of response to immunotherapy in 198 patients with metastatic non-microcytic lung cancer (mNSCLC): real world data from 2 university hospitals in Spain
Presenter: Juan Felipe Cordoba Ortega
Session: Poster Display session 3
Resources:
Abstract
5645 - Evaluating Lung CT Density Changes Among Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) Treated with Thoracic Radiotherapy (TRT) alone or TRT Followed by Combined Ipilimumab (IPI) and Nivolumab (NIVO).
Presenter: Kujtim Latifi
Session: Poster Display session 3
Resources:
Abstract
1540 - Immuno-oncology therapy biomarkers differences between polyoma-virus positive and negative Merkel cell carcinomas
Presenter: Zoran Gatalica
Session: Poster Display session 3
Resources:
Abstract
4538 - Can we improve patient selection for phase 1 clinical trials (Ph1) based on Immuno-Oncology score prognostic index (VIO)?
Presenter: Ignacio Matos Garcia
Session: Poster Display session 3
Resources:
Abstract
5544 - Evaluation of a radiomic signature of CD8 cells in patients treated with immunotherapy-radiotherapy in three clinical trials.
Presenter: Roger Sun
Session: Poster Display session 3
Resources:
Abstract